Literature DB >> 19509563

miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma.

Richard Flavin1, Paul Smyth, Ciara Barrett, S Russell, Hannah Wen, Jianjun Wei, Alex Laios, Sharon O'Toole, M Ring, K Denning, J Li, S Aherne, D Sammarae, N A Aziz, A Alhadi, Sephen P Finn, M Loda, Sheppard B, Orla Sheils, John J O'Leary.   

Abstract

Micro-RNAs are a group of small noncoding RNAs approximately 22 nucleotides in length. Recent work has shown differential expression of mature micro-RNAs in human cancers. We characterized the alteration in expression of miR-29b in ovarian serous carcinoma. miR-29b expression was analyzed using quantitative stem-loop reverse transcriptase polymerase chain reaction on a set of 50 formalin-fixed, paraffin-embedded ovarian serous carcinoma samples. Protein expression of p53, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, and insulinlike growth factor 1 was quantified in the corresponding tissue microarray. The expression profile of miR-29b was correlated with clinicopathological and patient survival data. We provide definitive evidence that miR-29b is down-regulated in a significant proportion of ovarian serous carcinomas and is associated with specific clinicopathological features, most notably high miR-29b expression being associated with reduced disease-free survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509563     DOI: 10.1111/IGC.0b013e3181a48cf9

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  24 in total

Review 1.  Minireview: The roles of small RNA pathways in reproductive medicine.

Authors:  Shannon M Hawkins; Gregory M Buchold; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2011-05-05

2.  HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.

Authors:  Jingjing Wu; Zhaojian Liu; Changshun Shao; Yaoqin Gong; Eva Hernando; Peng Lee; Masashi Narita; William Muller; Jinsong Liu; Jian-Jun Wei
Journal:  Cancer Res       Date:  2011-01-11       Impact factor: 12.701

Review 3.  Genome-wide analysis of microRNA and mRNA expression signatures in cancer.

Authors:  Ming-hui Li; Sheng-bo Fu; Hua-sheng Xiao
Journal:  Acta Pharmacol Sin       Date:  2015-08-24       Impact factor: 6.150

4.  MicroRNA-149 suppresses the proliferation and increases the sensitivity of ovarian cancer cells to cisplatin by targeting X-linked inhibitor of apoptosis.

Authors:  Lin Sun; Ruixia Zhai; Li Zhang; Shuping Zhao
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

5.  Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease.

Authors:  Magali Fasseu; Xavier Tréton; Cécile Guichard; Eric Pedruzzi; Dominique Cazals-Hatem; Christophe Richard; Thomas Aparicio; Fanny Daniel; Jean-Claude Soulé; Richard Moreau; Yoram Bouhnik; Marc Laburthe; André Groyer; Eric Ogier-Denis
Journal:  PLoS One       Date:  2010-10-05       Impact factor: 3.240

Review 6.  Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Authors:  Marta Szajnik; Małgorzata Czystowska-Kuźmicz; Esther Elishaev; Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2016-06-23       Impact factor: 5.225

7.  miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Tumour Biol       Date:  2015-11-12

Review 8.  Clinically relevant microRNAs in ovarian cancer.

Authors:  Shu Zhang; Zhen Lu; Anna K Unruh; Cristina Ivan; Keith A Baggerly; George A Calin; Zongfang Li; Robert C Bast; Xiao-Feng Le
Journal:  Mol Cancer Res       Date:  2014-10-10       Impact factor: 5.852

Review 9.  The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.

Authors:  Priya Samuel; David Raul Francisco Carter
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

Review 10.  Therapeutic advances in women's cancers.

Authors:  Amy R Carroll; Robert L Coleman; Anil K Sood
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.